person · Reporting owner
Doughty Christopher Grant
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | Chief Business Officer | December 15, 2025 | December 17, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date December 15, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 62,194 |
Ending reported balance
After 2025-12-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-12-15 · Grant · Acquired 14,714 · Balance 54,194 F1: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Row 2 · 2025-12-15 · Grant · Acquired 8,000 · Balance 62,194 F1: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.21 · Expires 2035-12-15 | Direct | 58,855 |
Reported balance
After 2025-12-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-15 · Grant · Acquired 58,855 · Balance 58,855 F2: This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.
F2: This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2025 Filed Dec 17, 2025 16:47 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantStock Option (Right to Buy) · Derivative | 58,855 | $0.00 Strike: $13.21 | $0.00 |
DisclosureSEC source: 0001628280-25-057685 · wk-form4_1766008052.xml · derivative · entry 3 Doughty Christopher Grant · CIK 0002074223 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,855 Underlying: Ordinary Shares · 58,855 shares Expires 2035-12-15 F2 · derivative.exercise_date: This Option represents a right to purchase shares of the Issuer's Ordinary Shares and vests with respect to 1/48th of the Option on each monthly anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:47 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 8,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057685 · wk-form4_1766008052.xml · nonDerivative · entry 2 Doughty Christopher Grant · CIK 0002074223 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,194 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 16:47 UTC | CRESCENT BIOPHARMA, INC. CBIO · Entity 5255 | GrantOrdinary Shares | 14,714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-057685 · wk-form4_1766008052.xml · nonDerivative · entry 1 Doughty Christopher Grant · CIK 0002074223 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,194 F1 · price: Represents an award of Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Ordinary Shares. The RSUs shall vest in approximately equal three-month installments through the four-year anniversary of December 15, 2025, subject to the Reporting Person remaining continuously employed by or providing services to the Issuer or its subsidiaries from December 15, 2025 through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.